From safety to efficacy
HAVING FINALISED our first in man trials. Our aim is to establish efficacy through Phase IIA Proof of Concept studies in one or more patient populations starting in 2024.
Therapeutic focus » The PharmNovo Journey
HAVING FINALISED our first in man trials. Our aim is to establish efficacy through Phase IIA Proof of Concept studies in one or more patient populations starting in 2024.
In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.
Read morePharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
Read moreWe are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Read more